Abstract 519P
Background
LC-SCRUM was established in 2013 to screen target genes in lung cancer to advance the development of new molecular targeted drugs and diagnostics. To date, with the cooperation of over 200 institutions across Japan, LC-SCRUM has performed genomic analysis of over 7000 lung cancer patients. Since Mar 2019, LC-SCRUM has expanded to Taiwan as genomic screening infrastructure with the cooperation of Asian countries. Here, we report initial results of Asian international genomic screening, LC-SCRUM-Asia.
Methods
Tumor samples of non-small cell lung cancer patients were analyzed for oncogenic alterations using targeted next-generation sequencing (NGS) with Oncomine Comprehensive Assay. The analysis was performed as central test at CLIA lab in Japan.
Results
As of May 31th in 2019, the LC-SCRUM-Asia has the participation of 5 institutions in Taiwan and 161 in Japan. For the first 2 month, a total of 477 patients (23 from Taiwan and 454 from Japan) were enrolled in this study. Median age were 68 years (range, 45-84) in Taiwan cohort and 67 (28-87) in Japan. In Taiwan 65% of patients were women, 70% adenocarcinoma and 70% non-smoker, and in Japan 37% of patients were women, 79% adenocarcinoma and 29% non-smoker, respectively. Of 13 analyzable patients in Taiwan, targeted NGS showed that 9 (69%) had at least one targetable oncogenic alterations, including 4 EGFR mut, 2 KRAS mut, 2 ALK fusinos and 1 RET fusions plus EGFR mut. Of 423 patients in Japan, 196 (46%) had at least one targetable oncogenic alterations. Oncogenic alterations commonly found were EGFR mut (19%), KRAS mut (13%), ALK fusions (2%), RET fusions (1%) and others in Japan.
Conclusions
Asian international genomic screening can be implemented between Taiwan and Japan settings. LC-SCRUM-Asia will contribute to further development of precision medicine for lung cancer patients in Asia. Updated results will be presented at the meeting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
LC-SCRUM-Asia.
Funding
AstraZeneca, Ignyta, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Taiho, Takeda, Merck Serono, Novartis, MSD, Pfizer, Lilly, Bristol-Myers Squibb, Chugai, Boehringer Ingelheim, Astellas, LOXO, Janssen, Thermo Fisher Scientific, Ono.
Disclosure
C-H.S. Kuo: Honoraria (self): AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self): Roche; Honoraria (self): Pfizer; Honoraria (self): Eli Lilly; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self): ONO Pharma; Honoraria (self), Advisory / Consultancy: Merck; Advisory / Consultancy: Chugai; Advisory / Consultancy: Takeda. K. Yoh: Honoraria (self): Chugai; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Taiho; Research grant / Funding (institution): MSD; Honoraria (self): Novartis. Y. Zenke: Honoraria (self): Boehringer Ingelheim; Honoraria (self): AstraZeneca; Honoraria (self): Lilly; Honoraria (self): Chugai; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self): Taiho; Honoraria (self): Ono pharmaceutical. S. Matsumoto: Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self): Pfizer; Honoraria (self), Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): MSD; Honoraria (self), Research grant / Funding (institution): Chugai Pharma. K. Goto: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Lilly; Honoraria (self), Research grant / Funding (institution): Chugai; Research grant / Funding (institution): Ignyta; Research grant / Funding (institution): Kyowa Hakko Kirin; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Taiho; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Astellas; Research grant / Funding (institution): LOXO; Research grant / Funding (institution): Janssen; Research grant / Funding (institution): Thermo Fisher Scientific; Research grant / Funding (institution): Ono. All other authors have declared no conflicts of interest.
Resources from the same session
457P - The prevalence of vitamin D deficiency in Thai cancer patients, its dynamics and association with cancer survival
Presenter: Chavapon Ngokngarm
Session: Poster display session
Resources:
Abstract
458P - Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC
Presenter: Martin Filipits
Session: Poster display session
Resources:
Abstract
460P - Mendelian randomization study showed no causality between metformin use and lung cancer risk
Presenter: Jiayi Shen
Session: Poster display session
Resources:
Abstract
461P - Blood trace minerals and lung cancer: A Mendelian randomization study
Presenter: Wei Xian
Session: Poster display session
Resources:
Abstract
463P - Prediction of invasiveness in lung adenocarcinoma using machine learning algorithm based on 3D-CT imaging
Presenter: Yusuke Saeki
Session: Poster display session
Resources:
Abstract
459P - Fish intake, dietary polyunsaturated fatty acids, and lung cancer: systematic review and dose-response meta-analysis of 1.7 million men and women
Presenter: Chao Cao
Session: Poster display session
Resources:
Abstract
462P - Usefulness for prevention of postoperative cerebrovascular complications in patients with lung cancer using carotid ultrasonography
Presenter: Sadanori Takeo
Session: Poster display session
Resources:
Abstract
468P - Histological type analysis of 10-year follow-up of WJTOG0105: A phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer
Presenter: Masahiro Tsuboi
Session: Poster display session
Resources:
Abstract
469P - Comparison of combined chemoradiotherapy regimens; Paclitaxel plus carboplatin and cisplatin plus etoposide for locally advanced non-small cell lung cancer: A randomised phase III trial
Presenter: Alper Ata
Session: Poster display session
Resources:
Abstract
472P - Integration of expression rate and absolute cell counts of PD-1+ stromal tumour-infiltrating lymphocytes: Prognostic significance in esophageal squamous cell carcinoma
Presenter: Qingkun Song
Session: Poster display session
Resources:
Abstract